Vorsetuzumab mafodotin (anti-CD70) is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the extracellular domain of the human CD70 molecule, and a cytotoxic tubulin polymerization inhibitor. It is used in the treatment of renal cell carcinoma. Purity
≥90%(SDS-PAGE&SEC)
Endotoxin Level < 1.0EU/mg
Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂
No
储存条件
-80℃储存,避免反复冻融
运输条件
特低温运输
稳定性与储存
在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
图片
Vorsetuzumab mafodotin (anti-CD70) (Ab183339) - Flow Cytometry Flow Cytometry analysis of Raji cells labelling CD70 (red) with Vorsetuzumab mafodotin (anti-CD70) (Ab183339). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Vorsetuzumab mafodotin (anti-CD70) (Ab183339) - ELISA Immobilized human CD70-his at 2.0 μg/mL can bind Vorsetuzumab mafodotin (anti-CD70) (Ab183339) with the EC
₅₀
of 1.37 μg/mL.
Vorsetuzumab mafodotin (anti-CD70) (Ab183339) - SEC The purity of Vorsetuzumab mafodotin (anti-CD70) (Ab183339) is more than 95% verified by HPLC.